Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00785928




Registration number
NCT00785928
Ethics application status
Date submitted
3/11/2008
Date registered
5/11/2008
Date last updated
10/07/2018

Titles & IDs
Public title
A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
Scientific title
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
Secondary ID [1] 0 0
H9B-MC-BCDH
Secondary ID [2] 0 0
12409
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - LY2127399
Treatment: Drugs - Placebo

Experimental: Placebo -

Experimental: 1 mg LY2127399 -

Experimental: 3 mg LY2127399 -

Experimental: 10 mg LY2127399 -

Experimental: 30 mg LY2127399 -

Experimental: 60 mg LY2127399 -

Experimental: 120 mg LY2127399 -


Treatment: Other: LY2127399
Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).

Treatment: Drugs: Placebo
Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 Response up to 24 Weeks
Timepoint [1] 0 0
Up to week 24
Secondary outcome [1] 0 0
Percentage of Participants Achieving The American College of Rheumatology (ACR)20 Response up to 24 Weeks
Timepoint [1] 0 0
Up to 24 weeks
Secondary outcome [2] 0 0
Change From Baseline in the Tender Joint Count up to 24 Weeks
Timepoint [2] 0 0
Baseline, up to 24 weeks
Secondary outcome [3] 0 0
Change From Baseline in Swollen Joint Count up to 24 Weeks
Timepoint [3] 0 0
Baseline, up to 24 weeks
Secondary outcome [4] 0 0
Change From Baseline in the Disease Activity Score (DAS) up to 24 Weeks
Timepoint [4] 0 0
Baseline, up to 24 weeks
Secondary outcome [5] 0 0
Percentage of Participants With A European League Against Rheumatism Responder Index Based on the 28 Joint Count (EULAR28) up to 24 Weeks
Timepoint [5] 0 0
Up to 24 weeks
Secondary outcome [6] 0 0
Change From Baseline in the Participant's Assessment of Joint Pain up to 24 Weeks
Timepoint [6] 0 0
Baseline, up to 24 weeks
Secondary outcome [7] 0 0
Change From Baseline in the Participant's Assessment of Disease Activity up to 24 Weeks
Timepoint [7] 0 0
Baseline, up to 24 weeks
Secondary outcome [8] 0 0
Change From Baseline in the Physician's Assessment of Disease Activity up to 24 Weeks
Timepoint [8] 0 0
Baseline, up to 24 weeks
Secondary outcome [9] 0 0
Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) up to 24 Weeks
Timepoint [9] 0 0
Baseline, up to 24 weeks
Secondary outcome [10] 0 0
Percent Change From Baseline in C-Reactive Protein (CRP) up to 24 Weeks
Timepoint [10] 0 0
Baseline, up to 24 weeks
Secondary outcome [11] 0 0
Change From Baseline in the Functional Assessment of Chronic Illness (FACIT) Fatigue Scale up to 24 Weeks
Timepoint [11] 0 0
Baseline, up to 24 weeks
Secondary outcome [12] 0 0
Change From Baseline in the Short Form Health Survey (SF-36) up to 24 Weeks
Timepoint [12] 0 0
Baseline, up to 24 weeks
Secondary outcome [13] 0 0
Pharmacokinetics of LY2127399: C-Trough Steady State Concentration at 24 Weeks
Timepoint [13] 0 0
24 weeks
Secondary outcome [14] 0 0
Pharmacokinetics of LY2127399: T-Half Life (t1/2, Tau) at 24 Weeks
Timepoint [14] 0 0
24 weeks
Secondary outcome [15] 0 0
Change From Baseline in the Absolute Total B Cell (CD20+CD3- Cells) Count up to 24 Weeks
Timepoint [15] 0 0
Baseline, up to 24 weeks
Secondary outcome [16] 0 0
Change From Baseline in Serum Immunoglobulin up to 24 Weeks
Timepoint [16] 0 0
Baseline, up to 24 weeks
Secondary outcome [17] 0 0
Number of Participants Experiencing An Adverse Event
Timepoint [17] 0 0
Baseline up to 24 weeks

Eligibility
Key inclusion criteria
* Have given written informed consent
* Women must not be at risk to become pregnant during study participation
* Diagnosis of Rheumatoid Arthritis (RA)
* Current, regular use of Methotrexate, at a stable dose
* Other criteria to be reviewed by study doctor
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Use of excluded medications(reviewed by study doctor)
* Have not failed biologic tumor necrosis factor-alpha (TNF-a) inhibitor therapy
* Have had recent or ongoing infection which, in the opinion of the study doctor put patient at an unacceptable risk for participation in the study
* Evidence of tuberculosis
* Have systemic inflammatory condition other than RA, such as juvenile RA, Crohn's disease, ulcerative colitis, psoriatic arthritis or seronegative spondyloarthropathy
* Other criteria to be reviewed by study doctor

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2010
Sample size
Target
Accrual to date
Final
158
Recruitment in Australia
Recruitment state(s)
QLD,SA
Recruitment hospital [1] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Brisbane
Recruitment hospital [2] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Maroochydore
Recruitment hospital [3] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Elizabeth Vale
Recruitment postcode(s) [1] 0 0
4066 - Brisbane
Recruitment postcode(s) [2] 0 0
4558 - Maroochydore
Recruitment postcode(s) [3] 0 0
5112 - Elizabeth Vale
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Pennsylvania
Country [5] 0 0
United States of America
State/province [5] 0 0
Texas
Country [6] 0 0
Argentina
State/province [6] 0 0
Buenos Aires
Country [7] 0 0
Argentina
State/province [7] 0 0
Quilmes
Country [8] 0 0
Chile
State/province [8] 0 0
Santiago
Country [9] 0 0
Chile
State/province [9] 0 0
Valdivia
Country [10] 0 0
Chile
State/province [10] 0 0
Vina Del Mar
Country [11] 0 0
Germany
State/province [11] 0 0
Leipzig
Country [12] 0 0
Hungary
State/province [12] 0 0
Budapest
Country [13] 0 0
Hungary
State/province [13] 0 0
Esztergom
Country [14] 0 0
Hungary
State/province [14] 0 0
Kistarcsa
Country [15] 0 0
Hungary
State/province [15] 0 0
Szolnok
Country [16] 0 0
India
State/province [16] 0 0
Hyderabaad
Country [17] 0 0
India
State/province [17] 0 0
Lucknow
Country [18] 0 0
India
State/province [18] 0 0
Pune
Country [19] 0 0
India
State/province [19] 0 0
Secunderabad
Country [20] 0 0
Mexico
State/province [20] 0 0
Chihuahua
Country [21] 0 0
Mexico
State/province [21] 0 0
Cuernavaca
Country [22] 0 0
Mexico
State/province [22] 0 0
Guadalajara
Country [23] 0 0
Mexico
State/province [23] 0 0
Mexico City
Country [24] 0 0
Mexico
State/province [24] 0 0
Monterrey
Country [25] 0 0
Mexico
State/province [25] 0 0
San Luis Potosi
Country [26] 0 0
Mexico
State/province [26] 0 0
Tampico
Country [27] 0 0
Poland
State/province [27] 0 0
Bialystok
Country [28] 0 0
Poland
State/province [28] 0 0
Chelm Slaski
Country [29] 0 0
Poland
State/province [29] 0 0
Elblag
Country [30] 0 0
Poland
State/province [30] 0 0
Krakow
Country [31] 0 0
Poland
State/province [31] 0 0
Lubin
Country [32] 0 0
Poland
State/province [32] 0 0
Lublin
Country [33] 0 0
Poland
State/province [33] 0 0
Poznan
Country [34] 0 0
Poland
State/province [34] 0 0
Torun
Country [35] 0 0
Poland
State/province [35] 0 0
Warsaw
Country [36] 0 0
Poland
State/province [36] 0 0
Wroclaw
Country [37] 0 0
Romania
State/province [37] 0 0
Brasov
Country [38] 0 0
Romania
State/province [38] 0 0
Targu-Mures
Country [39] 0 0
Slovakia
State/province [39] 0 0
Bratislava
Country [40] 0 0
Slovakia
State/province [40] 0 0
Rimavska
Country [41] 0 0
Ukraine
State/province [41] 0 0
Ivano-Frankivsk
Country [42] 0 0
Ukraine
State/province [42] 0 0
Kiev
Country [43] 0 0
Ukraine
State/province [43] 0 0
Odessa
Country [44] 0 0
Ukraine
State/province [44] 0 0
Simferopol

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To assess the efficacy of LY2127399 versus placebo using American College of Rheumatology (ACR)50 response scale at 24 weeks
Trial website
https://clinicaltrials.gov/study/NCT00785928
Trial related presentations / publications
Genovese MC, Lee E, Satterwhite J, Veenhuizen M, Disch D, Berclaz PY, Myers S, Sides G, Benichou O. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2013 Sep 1;72(9):1453-60. doi: 10.1136/annrheumdis-2012-202864. Epub 2013 Apr 18.
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLy (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00785928